Emergency contraception and the LNG-IUS.

Contraception: The Effective and Appropriate Use of Longacting Reversible Contraception. London, UK: RCOG Press, October 2005 http://www.nice.org.uk/pdf/ CG030fullguideline.pdf [Accessed 7 February 2006]. 2 Jarvela I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998; 13: 3379–3383. 3 Schering Health Care Limited. Mirena: Summary of Product Characteristics. http://www.emc.medicines.org.uk/ [Accessed 15 May 2006]. 4 Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004; 30: 99–109. 5 Inki P, Hurskainen R, Palo P, Ekholm E, Grenman S, Kivelä A, et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 2002; 20: 381–385. 6 Teichmann AT, Brill K, Albring M, Schnitker J, Wojtynek P, Kustra E. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecol Endocrinol 1995; 9: 299–305. 7 Westhof C, Clark C. Benign cysts in England and Wales and the United States. Br J Obstet Gynaecol 1992; 99: 329–332. 8 Royal College of Obstetricians and Gynaecologists (RCOG). Ovarian Cysts in Postmenopausal Women (RCOG Guideline No. 34). London, UK: RCOG Press, October 2003. http://www.rcog.org.uk/resources/Public/pdf/ Ovarian_Cysts_No34.pdf [Accessed 15 May 2006]. 9 Sturridge F, Guillebaud J. A risk–benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 1996; 15: 430–440.